Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 99
Filter
Add more filters

Publication year range
1.
Mol Psychiatry ; 27(5): 2546-2553, 2022 05.
Article in English | MEDLINE | ID: mdl-35288633

ABSTRACT

Deep brain stimulation (DBS) to the superolateral branch of the medial forebrain bundle (MFB) has emerged as a quite efficacious therapy for treatment resistant depression (TRD), leading to rapid antidepressant effects. In this study, we complete our assessment of our first 10 enrolled patients throughout one year post-implantation, showing sustained antidepressant effect up to 5 years. The primary outcome measure was a 50% reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) score, which was interpreted as a response. Deterministic fiber tracking was used to individually map the target area. An insertional effect was seen during the 4-week sham stimulation phase (29% mean MADRS reduction, p = 0.02). However, after 2 weeks of initiating stimulation, five patients met response criteria (47% mean MADRS reduction, p < 0.001). One patient withdrew from study participation at 6 weeks. Twelve weeks after initiating stimulation, six of nine remaining patients had a >50% decrease in MADRS scores relative to baseline (52% mean MADRS reduction, p = 0.001); these same six patients continued to meet response criteria at 52 weeks (63% overall mean MADRS reduction, p < 0.001). Four of five patients who achieved the 5-year time point analysis continued to be responders (81% mean MADRS reduction, p < 0.001). Evaluation of modulated fiber tracts reveals significant common prefrontal/orbitofrontal connectivity to the target region in all responders. Key points learned from this study that we can incorporate in future protocols to better elucidate the effect of this therapy are a longer blinded sham stimulation phase and use of scheduled discontinuation concomitant with functional imaging.


Subject(s)
Deep Brain Stimulation , Depressive Disorder, Treatment-Resistant , Antidepressive Agents/therapeutic use , Deep Brain Stimulation/methods , Depressive Disorder, Treatment-Resistant/therapy , Humans , Medial Forebrain Bundle/physiology , Treatment Outcome
2.
Mol Psychiatry ; 27(3): 1362-1372, 2022 03.
Article in English | MEDLINE | ID: mdl-35022529

ABSTRACT

The pathophysiological mechanisms underlying bipolar (BD) and major depressive disorders (MDD) are multifactorial but likely involve synaptic dysfunction and dysregulation. There are multiple synaptic proteins but three synaptic proteins, namely SNAP-25, PSD-95, and synaptophysin, have been widely studied for their role in synaptic function in human brain postmortem studies in BD and MDD. These studies have yielded contradictory results, possibly due to the small sample size and sourcing material from different cortical regions of the brain. We performed a systematic review and meta-analysis to understand the role of these three synaptic proteins and other synaptic proteins, messenger RNA (mRNA) and their regional localizations in BD and MDD. A systematic literature search was conducted and the review is reported in accordance with the MOOSE Guidelines. Meta-analysis was performed to compare synaptic marker levels between BD/MDD groups and controls separately. 1811 papers were identified in the literature search and screened against the preset inclusion and exclusion criteria. A total of 72 studies were screened in the full text, of which 47 were identified as eligible to be included in the systematic review. 24 of these 47 papers were included in the meta-analysis. The meta-analysis indicated that SNAP-25 protein levels were significantly lower in BD. On average, PSD-95 mRNA levels were lower in BD, and protein levels of SNAP-25, PSD-95, and syntaxin were lower in MDD. Localization analysis showed decreased levels of PSD-95 protein in the frontal cortex. We found specific alterations in synaptic proteins and RNAs in both BD and MDD. The review was prospectively registered online in PROSPERO international prospective register of systematic reviews, registration no. CRD42020196932.


Subject(s)
Bipolar Disorder , Depressive Disorder, Major , Brain , Depressive Disorder, Major/genetics , Disks Large Homolog 4 Protein/genetics , Humans , Mood Disorders , RNA, Messenger
3.
Psychopathology ; 56(1-2): 109-116, 2023.
Article in English | MEDLINE | ID: mdl-35640542

ABSTRACT

The progressively improving understanding of the borderline personality disorder (BPD) has led to an increased interest in the better clarification of the integrated role of biological and psychosocial factors in the underlying pathophysiology of this condition. The influence of early childhood interactions and stress exposure in shaping our personalities during adulthood cannot be emphasized enough. In this review, we discuss the critical role of parenting-related factors including maladaptive parenting, parenting styles, and parenting psychopathology as early childhood influences in the developmental psychopathology of BPD. Protective factors that may impact the development of this disorder and possible preventive interventions are also briefly reviewed.


Subject(s)
Borderline Personality Disorder , Parenting , Child, Preschool , Humans , Adult , Parenting/psychology , Borderline Personality Disorder/psychology , Psychopathology , Personality
4.
Mol Psychiatry ; 26(8): 4117-4126, 2021 08.
Article in English | MEDLINE | ID: mdl-33173193

ABSTRACT

Abnormalities within frontal lobe gray and white matter of bipolar disorder (BD) patients have been consistently reported in adult and pediatric studies, yet little is known about the neurochemistry of the anterior white matter (AWM) in pediatric BD and how medication status may affect it. The present cross-sectional 3T 1H MRS study is the first to use a multivoxel approach to study the AWM of BD youth. Absolute metabolite levels from four bilateral AWM voxels were collected from 49 subjects between the ages of 8 and 18 (25 healthy controls (HC); 24 BD) and quantified. Our study found BD subjects to have lower levels of N-acetylaspartate (NAA) and glycerophosphocholine plus phosphocholine (GPC + PC), metabolites that are markers of neuronal viability and phospholipid metabolism and have also been implicated in adult BD. Further analysis indicated that the observed patterns were mostly driven by BD subjects who were medicated at the time of scanning and had an ADHD diagnosis. Although limited by possible confounding effects of mood state, medication, and other mood comorbidities, these findings serve as evidence of altered neurochemistry in BD youth that is sensitive to medication status and ADHD comorbidity.


Subject(s)
Bipolar Disorder , Neurochemistry , White Matter , Adolescent , Adult , Child , Cross-Sectional Studies , Humans , Proton Magnetic Resonance Spectroscopy , White Matter/diagnostic imaging
5.
Mol Psychiatry ; 26(8): 4158-4178, 2021 08.
Article in English | MEDLINE | ID: mdl-33230205

ABSTRACT

The importance of tryptophan as a precursor for neuroactive compounds has long been acknowledged. The metabolism of tryptophan along the kynurenine pathway and its involvement in mental disorders is an emerging area in psychiatry. We performed a meta-analysis to examine the differences in kynurenine metabolites in major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SZ). Electronic databases were searched for studies that assessed metabolites involved in the kynurenine pathway (tryptophan, kynurenine, kynurenic acid, quinolinic acid, 3-hydroxykynurenine, and their associate ratios) in people with MDD, SZ, or BD, compared to controls. We computed the difference in metabolite concentrations between people with MDD, BD, or SZ, and controls, presented as Hedges' g with 95% confidence intervals. A total of 101 studies with 10,912 participants were included. Tryptophan and kynurenine are decreased across MDD, BD, and SZ; kynurenic acid and the kynurenic acid to quinolinic acid ratio are decreased in mood disorders (i.e., MDD and BD), whereas kynurenic acid is not altered in SZ; kynurenic acid to 3-hydroxykynurenine ratio is decreased in MDD but not SZ. Kynurenic acid to kynurenine ratio is decreased in MDD and SZ, and the kynurenine to tryptophan ratio is increased in MDD and SZ. Our results suggest that there is a shift in the tryptophan metabolism from serotonin to the kynurenine pathway, across these psychiatric disorders. In addition, a differential pattern exists between mood disorders and SZ, with a preferential metabolism of kynurenine to the potentially neurotoxic quinolinic acid instead of the neuroprotective kynurenic acid in mood disorders but not in SZ.


Subject(s)
Bipolar Disorder , Depressive Disorder, Major , Schizophrenia , Humans , Kynurenic Acid , Kynurenine
6.
CNS Spectr ; 27(5): 639-644, 2022 10.
Article in English | MEDLINE | ID: mdl-34121653

ABSTRACT

BACKGROUND: Altered peripheral immune/inflammatory system and brain volumetric changes have been implicated in the pathophysiology of bipolar disorder (BD). This study aimed to evaluate how peripheral levels of cytokines are related to volumetric brain changes in euthymic patients with BD. METHODS: Euthymic patients with BD (n = 21) and healthy controls (n = 22) were enrolled in this exploratory study. Blood samples were collected on the same day of clinical assessment and neuroimaging. Cytokines were measured through cytometric bead array method. Neuroimaging data were acquired using a sagittal three-dimensional magnetic resonance imaging T1-weighted fast field echo sequence and was processed using FreeSurfer. RESULTS: Compared to controls, BD patients had significantly lower volumes in the cingulate, medial-orbitofrontal (MOF) and parahippocampal regions. We found a negative correlation between right MOF volume and interferon-gamma levels (ß = -0.431, P = .049) and a positive correlation between interleukin-10 levels and left posterior cingulate volume (ß = 0.457, P = .048). CONCLUSION: Our results support the involvement of inflammatory pathways in structural brain changes in BD.


Subject(s)
Bipolar Disorder , Humans , Gray Matter/pathology , Interleukin-10 , Inflammation Mediators , Interferon-gamma , Magnetic Resonance Imaging/methods , Brain
7.
CNS Spectr ; 27(6): 709-715, 2022 12.
Article in English | MEDLINE | ID: mdl-34044907

ABSTRACT

BACKGROUND: Bipolar disorder (BD) is a severe psychiatric disorder associated with structural and functional brain abnormalities, some of which have been found in unaffected relatives as well. In this study, we examined the potential role of decreased fractional anisotropy (FA) as a BD endophenotype, in adolescents at high risk for BD. METHODS: We included 15 offspring of patients with BD, 16 pediatric BD patients, and 16 matched controls. Diffusion weighted scans were obtained on a 3T scanner using an echo-planar sequence. Scans were segmented using FreeSurfer. RESULTS: Our results showed significantly decreased FA in six brain areas of offspring group; left superior temporal gyrus (LSTG; P < .0001), left transverse temporal gyrus (LTTG; P = .002), left banks of the superior temporal sulcus (LBSTS; P = .002), left anterior cingulum (LAC; P = .003), right temporal pole (RTP; P = .004) and left frontal pole (LFP; P = .017). On analysis, LSTG, LAC, and RTP demonstrated a potential to be an endophenotype when comparing all three groups. FA values in three regions, LBSTS, LTTG, and LFP were increased only in controls. CONCLUSION: Our findings point at decreased FA as a possible endophenotype for BD, as they were found in children of patients with BD. Most of these areas were previously found to have morphological and functional changes in adult and pediatric BD, and are thought to play important roles in affected domains of functioning. Prospective follow up studies should be performed to detect reliability of decreased FA as an endophenotype and effects of treatment on FA.


Subject(s)
Bipolar Disorder , Adult , Adolescent , Humans , Child , Anisotropy , Bipolar Disorder/diagnosis , Endophenotypes , Diffusion Tensor Imaging/methods , Prospective Studies , Reproducibility of Results
8.
Adv Exp Med Biol ; 1305: 429-445, 2021.
Article in English | MEDLINE | ID: mdl-33834411

ABSTRACT

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and a considerable portion of depressed patients does not respond well to available treatment strategies. Algorithm-based treatment may contribute to improving the MDD outcomes and have the potential to homogenize the pharmacological treatment of MDD patients, facilitating outcome research and cost-effectiveness analysis. This chapter provides a critical review of the available literature on the use of treatment algorithms for the management of MDD. The main available algorithms, their effectiveness, and challenges and limitations associated with their development are discussed. Finally, we provide a discussion of the future direction of algorithm-based treatments for MDD.


Subject(s)
Depressive Disorder, Major , Psychopharmacology , Algorithms , Cost-Benefit Analysis , Depressive Disorder, Major/drug therapy , Humans
9.
Med Teach ; 41(7): 842-843, 2019 07.
Article in English | MEDLINE | ID: mdl-30134754

ABSTRACT

The author, originally a full-trained psychiatrist in his home country, describes his personal experience as a resident physician in the Unites States, from a critical standpoint. The challenges and peculiarities inherent to undergoing second residency training are addressed. The singularities of the situation in question are discussed. Finally, the author provides some recommendations for teaching physicians involved in the supervision of residents, emphasizing the need for taking into consideration their trainee's respective backgrounds and their potential implications.


Subject(s)
Attitude of Health Personnel , Internship and Residency/organization & administration , Students, Medical/psychology , Humans
11.
Neuroimage ; 145(Pt B): 254-264, 2017 01 15.
Article in English | MEDLINE | ID: mdl-26883067

ABSTRACT

Diagnosis, clinical management and research of psychiatric disorders remain subjective - largely guided by historically developed categories which may not effectively capture underlying pathophysiological mechanisms of dysfunction. Here, we report a novel approach of identifying and validating distinct and biologically meaningful clinical phenotypes of bipolar disorders using both unsupervised and supervised machine learning techniques. First, neurocognitive data were analyzed using an unsupervised machine learning approach and two distinct clinical phenotypes identified namely; phenotype I and phenotype II. Second, diffusion weighted imaging scans were pre-processed using the tract-based spatial statistics (TBSS) method and 'skeletonized' white matter fractional anisotropy (FA) and mean diffusivity (MD) maps extracted. The 'skeletonized' white matter FA and MD maps were entered into the Elastic Net machine learning algorithm to distinguish individual subjects' phenotypic labels (e.g. phenotype I vs. phenotype II). This calculation was performed to ascertain whether the identified clinical phenotypes were biologically distinct. Original neurocognitive measurements distinguished individual subjects' phenotypic labels with 94% accuracy (sensitivity=92%, specificity=97%). TBSS derived FA and MD measurements predicted individual subjects' phenotypic labels with 76% and 65% accuracy respectively. In addition, individual subjects belonging to phenotypes I and II were distinguished from healthy controls with 57% and 92% accuracy respectively. Neurocognitive task variables identified as most relevant in distinguishing phenotypic labels included; Affective Go/No-Go (AGN), Cambridge Gambling Task (CGT) coupled with inferior fronto-occipital fasciculus and callosal white matter pathways. These results suggest that there may exist two biologically distinct clinical phenotypes in bipolar disorders which can be identified from healthy controls with high accuracy and at an individual subject level. We suggest a strong clinical utility of the proposed approach in defining and validating biologically meaningful and less heterogeneous clinical sub-phenotypes of major psychiatric disorders.


Subject(s)
Bipolar Disorder/diagnosis , Diffusion Magnetic Resonance Imaging/methods , Machine Learning , Neuroimaging/methods , White Matter/diagnostic imaging , Adult , Bipolar Disorder/diagnostic imaging , Bipolar Disorder/physiopathology , Female , Humans , Male , Middle Aged , Phenotype , Sensitivity and Specificity
12.
Cogn Neuropsychiatry ; 22(4): 298-314, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28490234

ABSTRACT

INTRODUCTION: Impulsivity is a multidimensional feature observed in bipolar disorder (BD) and substance use disorder (SUD). We previously found a relationship between SUD and risk taking in BD. It is still unclear whether self-rated and behavioral impulsivity measures differ between BD with and without comorbid SUD, or are specific to BD. METHODS: 93 adults with BD with comorbid SUD, 91 BD without SUD, and 93 healthy controls (HC) were administered the Barratt Impulsivity Scale (BIS), the Behavioral Inhibition/Behavioral Activation System Scale (BIS/BAS), and the Cambridge Neuropsychological Test Automated Battery. Analyses compared impulsivity measures across groups controlling for age. Discriminant function analyses (DFA) assessed the combination of variables effectively predicting group membership. RESULTS: BD displayed increased BIS, BIS/BAS scores, reduced performance on the Cambridge Gambling and Rapid Visual Processing, and Affective Go/No-Go tasks compared to HC. Comparisons between BD with and without SUD showed increased BIS Motor impulsiveness. The overall predictive power of DFA was weak. CONCLUSIONS: Some facets of impulsivity are a core trait of BD and are partially independent from the presence of SUD. Motor impulsiveness may be distinctive of BD+SUD. More research is needed to understand the role of impulsive behaviors as risk factors for relapse in SUD.


Subject(s)
Bipolar Disorder/psychology , Impulsive Behavior , Substance-Related Disorders/psychology , Adult , Alcoholism/psychology , Case-Control Studies , Comorbidity , Female , Humans , Inhibition, Psychological , Male , Middle Aged , Neuropsychological Tests , Psychiatric Status Rating Scales , Risk-Taking , Young Adult
17.
Am J Ther ; 22(6): 477-86, 2015.
Article in English | MEDLINE | ID: mdl-25383489

ABSTRACT

Bipolar disorder (BD) is associated with important cognitive deficits that persist during the periods of remission. Although these deficits seem to play an important role in the functional impairment experienced by bipolar patients, evidence regarding their clinical management is scant. We revised the databases PubMed, MEDLINE, and clinicaltrials.gov, searching for studies focusing on the pharmacological and nonpharmacological treatment of cognitive deficits among bipolar patients. In addition, a manual search of bibliographical cross-references was performed. Currently, there is no Food and Drug Administration-approved pharmacological agent for the management of cognitive deficits in BD. A number of agents have been tested in the treatment of cognitive deficits in BD, with mixed results. Nonpharmacological interventions, such as cognitive remediation and noninvasive brain stimulation techniques, seem promising, but their role has not yet been properly explored among bipolar patients. Additional studies, aiming at evaluating the efficacy of interventions combining cognitive rehabilitation and biological treatments, are highly desirable.


Subject(s)
Bipolar Disorder/complications , Cognition Disorders/drug therapy , Anticonvulsants/pharmacology , Antioxidants/therapeutic use , Antipsychotic Agents/pharmacology , Benzothiazoles/therapeutic use , Bipolar Disorder/drug therapy , Cholinesterase Inhibitors/therapeutic use , Cognition/drug effects , Humans , Insulin/administration & dosage , Lithium/pharmacology , Memantine/therapeutic use , Mifepristone/therapeutic use , Pramipexole
18.
Bipolar Disord ; 16(2): 204-7, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24350654

ABSTRACT

BACKGROUND: Although highly controversial, the treatment of obesity with exogenous human chorionic gonadotropin (HCG) remains popular in the USA. We report the case of a patient whose first manic episode was associated with the use of HCG for weight loss. CASE REPORT: A 32-year-old female patient was admitted to our psychiatric inpatient unit due to a two-week history of manic symptoms. She had no previous history of manic or hypomanic episodes and had completed a 45-day course of sublingual HCG for weight loss immediately prior to the onset of the manic episode. The patient was treated with lithium carbonate and aripiprazole, and progressed with improvement in the symptoms. CONCLUSION: While it is not possible to definitively link the HCG use to the development of mania, available evidence suggests that HCG may have a contributing role in triggering manic symptomatology.


Subject(s)
Bipolar Disorder/chemically induced , Gonadotropins/adverse effects , Adult , Female , Humans , Obesity/drug therapy
19.
Compr Psychiatry ; 55(3): 422-5, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24332386

ABSTRACT

OBJECTIVE: There are still several concerns regarding the inconsistency in the diagnosis of Bipolar Disorder (BD) in children and adolescents. This study reviews the symptoms of youth admitted to The University of Texas Harris County Psychiatric Center (UT-HCPC) prior to a confirmed diagnosis of BD to elucidate patterns and target symptoms which may facilitate early recognition of BD. METHODS: This is a retrospective review of charts of adult patients with a discharge diagnosis of BD for three consecutive admissions who were also admitted to UT-HCPC as children or adolescents (N=26). The Kiddie SADS was completed based on each patient's first admission as a child and last admission as an adult. RESULTS: Most of the symptoms found in adult BD were present in the child/adolescent subjects at equivalent rates, except for mood elevation, which was less common during childhood and adolescence. In spite of the psychopathological similarity, only 6 (23%) of the subjects were diagnosed with BD as youth. CONCLUSION: BD is poorly diagnosed among children and adolescents. Difficulties in the assessment of the youth, as well as particularities in the psychopathology of mood among children and adolescents may account for the low diagnostic rate.


Subject(s)
Bipolar Disorder/diagnosis , Bipolar Disorder/psychology , Depression/diagnosis , Irritable Mood , Adolescent , Adult , Depression/psychology , Female , Humans , Male , Psychiatric Status Rating Scales , Retrospective Studies
20.
Compr Psychiatry ; 55(6): 1337-41, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24889339

ABSTRACT

OBJECTIVE: Increased impulsivity seems to be present across all phases of bipolar disorder (BD). Impulsivity may therefore represent an endophenotype for BD, if it is also found among normal individuals at high genetic risk for mood disorders. In this study, we assessed impulsivity across four different groups of children and adolescents: patients with BD, major depressive disorder (MDD) patients, unaffected offspring of bipolar parents (UO), and healthy controls (HC). SUBJECTS AND METHODS: 52 patients with BD, 31 with MDD, 20 UO, and 45 HC completed the Barratt Impulsiveness Scale (BIS-11), an instrument designed to measure trait impulsivity. RESULTS: UO displayed significantly higher total BIS-11 impulsivity scores than HC (p=0.02) but lower scores than BD patients (F=27.12, p<0.01). Multiple comparison analysis revealed higher BIS-11 total scores among BD patients when compared to HC (p<0.01) and UO (p<0.01). MDD patients had higher BIS-11 scores when compared to HC (p<0.01). Differences between MDD patients and UO, as well as between MDD and BD patients, were not statistically significant. CONCLUSION: Our findings suggest that trait impulsivity is increased among children and adolescents with mood disorders, as well as in unaffected individuals at high genetic risk for BD.


Subject(s)
Bipolar Disorder/diagnosis , Depressive Disorder, Major/psychology , Endophenotypes , Impulsive Behavior , Parents/psychology , Adolescent , Adult , Bipolar Disorder/genetics , Case-Control Studies , Child , Depressive Disorder, Major/genetics , Female , Genetic Predisposition to Disease , Humans , Interview, Psychological , Male , Psychological Tests , Risk Factors , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL